Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.
Covered in this story
Call it yourself
No calls on $CNS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Cohen & Steers Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.